TNYA vs. ADAP, QURE, PGEN, ABSI, BCAB, IMTX, INBX, RLAY, MESO, and HUMA
Should you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Adaptimmune Therapeutics (ADAP), uniQure (QURE), Precigen (PGEN), Absci (ABSI), BioAtla (BCAB), Immatics (IMTX), Inhibrx (INBX), Relay Therapeutics (RLAY), Mesoblast (MESO), and Humacyte (HUMA). These companies are all part of the "medical" sector.
Adaptimmune Therapeutics (NASDAQ:ADAP) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment.
Adaptimmune Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
Adaptimmune Therapeutics currently has a consensus price target of $2.79, indicating a potential upside of 170.63%. Tenaya Therapeutics has a consensus price target of $15.00, indicating a potential upside of 301.07%. Given Adaptimmune Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenaya Therapeutics is more favorable than Adaptimmune Therapeutics.
In the previous week, Tenaya Therapeutics had 1 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 2 mentions for Tenaya Therapeutics and 1 mentions for Adaptimmune Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.00 equaled Adaptimmune Therapeutics'average media sentiment score.
Tenaya Therapeutics has a net margin of 0.00% compared to Tenaya Therapeutics' net margin of -890.13%. Adaptimmune Therapeutics' return on equity of -76.38% beat Tenaya Therapeutics' return on equity.
31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 32.8% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Adaptimmune Therapeutics has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500.
Adaptimmune Therapeutics received 283 more outperform votes than Tenaya Therapeutics when rated by MarketBeat users. However, 76.47% of users gave Tenaya Therapeutics an outperform vote while only 62.42% of users gave Adaptimmune Therapeutics an outperform vote.
Summary
Tenaya Therapeutics beats Adaptimmune Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Tenaya Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tenaya Therapeutics Competitors List
Related Companies and Tools
